There is a common misconception, especially among older adults, that depression is a normal part of aging. It’s not.
Explore the resources below to learn more about treating depression in older adults and how the GeneSight® Psychotropic test can help.
Clinicians may face many challenges when treating older adults, such as increased drug-drug interactions and higher rates of side effects.
The GeneSight Psychotropic test may help. The GeneSight test is a pharmacogenomic test that evaluates genetic variations in your patient’s DNA, and the results can inform you on how your patient may metabolize or respond to medications commonly prescribed to treat depression, anxiety, ADHD and other psychiatric conditions.
In addition to the typical symptoms of depression (persistent feelings of sadness, irritability, loss of interest in activities, feelings of hopelessness and worthlessness, and sometimes, thoughts of suicide1, older adults may exhibit additional symptoms, including:
such as wanting to stay home rather than socialize or do new things
such as physical aches or pains, fatigue, or loss of appetite
such as an inability to concentrate or remember things
When treating elderly patients for depression, clinicians may face challenges such as:
Elderly patients may also have impaired production of CYP450 enzymes which could affect drug metabolism rate.
To help avoid the problems that can result from these factors, physicians can reference published guidelines to help make critical medication decisions. The GeneSight test can also provide genetic information to help inform a clinician’s medication selection.
The GeneSight test provides genetic insights to help inform your clinician’s treatment plan, potentially reducing medication trial and error, and shortening your road to recovery.
The report also includes information on how a patient’s smoking status may affect their body’s metabolism of certain medications.
The report classifies over 60 mental health medications into three categories.
The GeneSight test results do not provide information on disease diagnosis, medication allergies, drug-drug interactions, or which medications will work best.
Patients 65 or older who were part of the GUIDED study and received the GeneSight Psychotropic test experienced:
Directional improvement in symptomsat week 8 compared to TAU
43% relative improvement in symptoms
8% absolute improvement in symptoms
Significantly higher response ratesat week 8 compared to TAU
84% relative improvement in response rates
14% absolute improvement in response rates
Significantly higher remission ratesat week 8 compared to TAU
172% relative improvement in remission rates
13% absolute improvement in remission rates